Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc. > Interview with CEO

View:

Post by SkywalkerofLuke on Mar 15, 2023 4:53pm

Interview with CEO

A survey in the US found that 5% of people (approximately 12.2 million adults) reported experiencing chronic cough in the previous 12 months. The chronic cough market is expected to reach $11.38B by 2029.

I’ve been following AGN.c AGNPF (a clinical stage drug development company).

This interview with their CEO gives updates on the previously announced 180 patient, 90-day Phase 2b clinical study of Ifenprodil for chronic cough that will begin in Q3.

As well, they announced earlier this month they’re planning to be the first company globally to investigate DMT for TBI in humans and are working towards a Phase 2 clinical trial in Q4.

https://www.youtube.com/watch?v=zpvV0-fELgc

180